ArriVent BioPharma, Inc. Common StockAVBPNASDAQ
Loading
Debt to Equity Over TimeCompressed
Percentile Rank25
3Y CAGR-61.5%
Studio
Year-over-Year Change

Debt-to-equity ratio

3Y CAGR
-61.5%/yr
Annual compound
Percentile
P25
Within normal range
vs 3Y Ago
0.1x
Contraction
Streak
2 yr
Consecutive declineCompressed
PeriodValueYoY Change
20250.00-93.3%
20240.00-67.4%
20230.00+163.0%
20220.00-
20210.00-